Annexon announces presentations highlighting anx007 functional and structural differentiation in geographic atrophy at the macula society 48th annual meeting

Brisbane, calif., feb. 13, 2025 (globe newswire) -- annexon, inc. (nasdaq: annx), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced presentations on anx007 in geographic atrophy (ga) at the macula society 48th annual meeting being held february 12-15 in charlotte harbor, florida.
ANNX Ratings Summary
ANNX Quant Ranking